Trump unveils tariffs up to 200% on generics

President Donald Trump announced a phased tariff plan for generic medicines, keeping imports at 0% for two years from August 1, 2026, before duties rise to 100% for one year and then to 200% by August 1, 2028. Market reaction pending.

"This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them," the president wrote.

India supplies a large share of US generics

Industry estimates based on US Food and Drug Administration and trade data suggest Indian companies supply a substantial share of finished generic medicines dispensed in the United States. Officials and industry executives say the phased timetable gives exporters a two-year window to adjust contracts and shipping plans.

Trade data show China remains the primary source of active pharmaceutical ingredients, which most manufacturers import to make finished drugs. Analysts note the tariff path raises the cost of finished-goods exports to the US and could push some firms to move production, seek tariff exemptions, or raise prices.

The immediate calendar to watch is August 1, 2026, when the 0% window ends; firms face a switch to 100% duties that day, and the schedule reaches 200% on August 1, 2028. Policymakers and companies will weigh reshoring investments against higher export costs and potential supply disruptions.